Glaxo keeps Ebola vax manufacturing in-house; 'Anti-typhoid' gene could improve vaccines;

> GlaxoSmithKline ($GSK) is keeping its Ebola vaccine production in-house. Report

> Scientists have found a gene variant that may provide better protection against typhoid fever. Report

> VaxInnate's quadrivalent seasonal influenza vaccine candidate has met its Phase I endpoints. Release

> Malaysian biotech Sentinext Therapeutics has successfully completed a $14 million Series B financing round that will take its hand, foot and mouth disease vaccine into Phase I clinical trials. More

> Abivax has inked a pact with the Finlay Institute to commercialize meningococcal and typhoid vaccines in Asia and Latin America. Release

> Malaria vaccine maker SutroVax is in search of Series A funding. More

And Finally... Unused flu vaccine costs California $1 million each year. More

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.